Key Points
- Frank Giustra purchased 100,000 shares of Biosig Technologies on Feb. 4 at $3.17 per share ($317,000), increasing his direct holding to 1,278,205 shares valued at about $4.05M (an 8.49% increase).
- Giustra also bought 1,000,000 shares on Jan. 23 at $3.00 per share ($3.0M), meaning his recent insider purchases total roughly $3.317M across 1.1M shares.
- Despite the insider buying, STEX opened at $3.13 and was down 5.7%, and analysts give the stock an average rating of Sell—Weiss Ratings initiated coverage with a "sell (d-)".
Biosig Technologies, Inc. (NASDAQ:STEX - Get Free Report) major shareholder Frank Giustra purchased 100,000 shares of the business's stock in a transaction on Wednesday, February 4th. The stock was acquired at an average cost of $3.17 per share, with a total value of $317,000.00. Following the completion of the acquisition, the insider directly owned 1,278,205 shares in the company, valued at $4,051,909.85. The trade was a 8.49% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Frank Giustra also recently made the following trade(s):
- On Friday, January 23rd, Frank Giustra bought 1,000,000 shares of Biosig Technologies stock. The stock was bought at an average price of $3.00 per share, for a total transaction of $3,000,000.00.
Biosig Technologies Stock Down 5.7%
STEX stock opened at $3.13 on Thursday. Biosig Technologies, Inc. has a 52-week low of $0.40 and a 52-week high of $14.11.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings started coverage on Biosig Technologies in a report on Friday, January 23rd. They issued a "sell (d-)" rating for the company. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of "Sell".
Get Our Latest Report on STEX
Biosig Technologies Company Profile
(
Get Free Report)
Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.
Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
